Tweet
<img alt="" height="1" width="1" />
Anadys Pharma Declines As ANA598 Data Doesn't Wow >ANDS
Wall Street Journal
NEW YORK (Dow Jones)--Anadys Pharmaceuticals Inc. (ANDS) shares fell Thursday after the preliminary data from a mid-stage study on the drug company's hepatitis C treatment didn't wow investors. ...
Anadys hepatitis C drug meets key study goalsBusinessWeek
Anadys Says Hep C Drug Shows Positive Results in TrialABC News
Anadys shares slump despite upbeat hep C dataFierceBiotech
MSN Money -Xconomy -PR Newswire (press release)
all 42 news articles »
More...